Breakthrough AI-Designed Treatment for Neglected Snakebite Disease Announced

US
Published:

In a significant advancement for neglected tropical diseases, researchers at the University of Washington, led by Nobel laureate David Baker, have developed an experimental treatment for snakebite envenoming using artificial intelligence. The disease, which claims over 100,000 lives annually, has long been overlooked by major pharmaceutical companies due to lack of funding for improved therapies.

Mexican biochemist Susana Vázquez, a key figure in the project, utilized AI programs RFdiffusion and ProteinMPNN to design novel proteins capable of neutralizing cobra venom. Preliminary animal studies showed promising results, with treated mice surviving lethal doses of venom. Vázquez expressed her excitement at the results, stating, “It was super exciting, because some of the mice had survived 100% of lethal doses of venom.”

This pioneering research highlights the potential role of AI in “democratizing” the drug discovery process, making it more accessible for conditions traditionally neglected. While current treatments rely on a century-old method of horse serum, this new approach could revolutionize therapeutic options for snake envenomation.

However, the challenge remains in the development and funding of clinical trials, as highlighted by experts in the field. The initial success with AI-designed proteins opens a pathway to explore solutions for various neglected diseases, but significant barriers to pharmaceutical development persist.

Vázquez’s study, published in the prestigious journal Nature, marks a hopeful step toward more effective treatments for snakebite victims across Africa, Asia, and Latin America, where the burden of snakebites is highest.

Weekly Newsletter

News summary by melangenews

Loading...

More from United States

Tragic Collision of Passenger Plane and Military Helicopter in Washington Claims 67 Lives

A catastrophic midair collision between a passenger plane and a military helicopter in Washington D.C. on Wednesday resulted in the deaths of all 67 individuals on board. The incident involved American Airlines flight 5342, which was a Bombardier CRJ-700 carrying 60 passengers and four crew members, and a military Sikorsky H-60 Black Hawk helicopter occupied by three service members. The collision occurred over the Potomac River at approximately 8:48 PM local time while the plane was making its final approach to Ronald Reagan Airport. Eyewitness reports indicated that the helicopter veered dangerously close to the aircraft before the impact, causing both to explode in midair. Emergency teams recovered 28 bodies from the plane and one from the helicopter, confirming that no survivors emerged from the wreckage. American Airlines expressed its condolences and stated that it is cooperating with investigation efforts, while President Donald Trump commented on the tragedy, stating it "seemed avoidable" given the clear weather conditions and routine approach procedure. A joint investigation by civil and military authorities is underway to determine the accident's cause.
US

FDA Approves Revolutionary Bioengineered Blood Vessel for Trauma Treatments

The U.S. Food and Drug Administration (FDA) has approved a groundbreaking bioengineered blood vessel aimed at addressing the needs of trauma patients. Developed by North Carolina-based Humacyte, this vessel is designed to integrate with a patient’s body over time, providing a solution for individuals who have suffered severe injuries that impede blood circulation, particularly in cases of amputation. According to founder and CEO Laura Niklason, traditional treatments using veins are often inadequate, especially when patients cannot provide usable options from their own bodies. The FDA approval follows extensive testing involving 51 civilian and 16 military patients, revealing that nearly 92% of the engineered vessels remained functional after 30 days, compared to 79% for synthetic alternatives. Additionally, the infection rate for the bioengineered vessels was under 1%, significantly lower than the over 8% rate associated with synthetic grafts, as published in the journal JAMA Surgery. While the approved application is limited to trauma cases, Humacyte is exploring additional uses for its technology, including potential applications in kidney dialysis and peripheral artery disease.
US

Trump Plans to Detain 30,000 Migrants at Guantanamo Bay

Former President Donald Trump has outlined a controversial plan to detain up to 30,000 migrants at the Guantanamo Bay detention facility if he is re-elected in 2024. According to a statement released by Trump's campaign, this measure aims to address illegal immigration and bolster national security. This proposal comes amidst intensifying discussions on immigration policies in the United States, reflecting Trump's previously embraced hardline stance during his presidency. Trump's administration was marked by strict immigration measures, including family separations and the construction of barriers along the U.S.-Mexico border. Critics of the plan have raised concerns about humanitarian implications and the legality of detaining a large number of migrants indefinitely. Legal experts argue that such actions could face significant pushback in courts. The proposal reflects a broader trend among certain political leaders advocating for stringent immigration control as a response to increasing cross-border migration. As the 2024 presidential election approaches, Trump's immigration policy is expected to be a focal point of debate among candidates.
US